Minimal cross-intolerance with nilotinib

hematologylibrary.org/search?author1=Jorge+E.+Cortes&sortspec=date&submit=Submit" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-style: none; font-weight: bold; font-style: inherit; font-size: inherit; font-family: inherit; line-height: inherit; text-align: inherit; vertical-align: 0px; text-decoration: none; color: rgb(51, 51, 51); white-space: nowrap; ">Jorge E. Cortes, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla-Ibarz, Elias Jabbour,Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, and Michele Baccarani

TAKE-HOME MESSAGE   This analysis of a phase II registration study corroborated that nilotinib is effective and well-tolerated in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant of imatinib.

http://bloodjournal.hematologylibrary.org/content/early/2011/04/04/blood-2010-11-318949.abstract